Imatinib Mesylate for Cerebral Langerhans'-Cell Histiocytosis
- 2 September 2004
- journal article
- letter
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 351 (10), 1034-1035
- https://doi.org/10.1056/nejm200409023511022
Abstract
Langerhans'-cell histiocytosis (LCH) is a rare disorder characterized by tissue infiltrates of CD1a+ Langerhans' cells, eosinophils, neutrophils, macrophages, and lymphocytes. Systemic treatments for refractory LCH are unsatisfactory and usually toxic. We report the use of imatinib mesylate to control parenchymal brain involvement in a patient with multisystem LCH.Keywords
This publication has 3 references indexed in Scilit:
- Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cellsBlood, 2004
- Modulation of Fibroblast Activity in Histiocytosis X by Platelet-Derived Growth FactorSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1995
- Activated human monocytes express the c-sis proto-oncogene and release a mediator showing PDGF-like activityNature, 1986